Clinical Trial Update: A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a "2+1"Sequential Schedule With bOPV in Infants [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating the immunogenicity and safety of sIPV in a 2+1 sequential schedule with bOPV in infants has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Poliomyelitis

Drugs mentioned

• sIPV (inactivated poliovirus vaccine) (sIPV)

Snippet

Sponsor: Sinovac Biotech Co., Ltd | Conditions: Poliomyelitis | Phase 3 | Status: COMPLETED